English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We have found that continuous intraarterial infusion of PGI2 alleviates rest pain and promotes healing of ischemic ulcers in patients with advanced arteriosclerosis obliterans. Since these effects could be related to the anti-platelet actions of prostacyclin, we studied serum levels of the platelet specific protein, a possible marker of platelet activation in vivo, named LA-PF4/βTG, and compared it with those of serum circulating platelet aggregates. The former was assessed by radioimmunoassay, the latter by method of Wu and Hoak. Determinations were carried out in 16 patients with arteriosclerosis obliterans, initially and during the second day of intraarterial infusion of PGI2 in a mean dose of 6 n9/kg/min. This therapy led to an almost uniform fall in circulating platelet aggregates. In contrast, levels of LA-PF4/β-TG antigen at the beginning of second day or the infusion /mean = 19.19 ng/ml, ± S.D. a 8.97/ did not differ significantly from the initial values /mean = 23.59 ng/ml, ± S.D. = 13.12/.  In conclusion: 1/ In our patients vascular disease did not produce any apparent increase in serum LA-PF4/β-TG antigen levels; 2/ Infusions of PGI2 did not affect basal levels of this platelet specific protein, while it markedly depressed the percent of circulating platelet aggregates.

Low Affinity Platelet Factor 4/β-Thromboglobulin (LA-PF4/βTG) Antigen And Circulating Platelet Aggregates During Prostacyclin (PGI2) Therapy